Lofexidine (Lucemyra) a central alpha-2 adrenergic agonist that mitigates the symptoms of opioid withdrawal.
Helps facilitate abrupt opioid discontinuation and adults.
Should be used in a comprehensive program.
May cause hypotension, bradycardia, and syncope and should be avoided in patients with severe coronary insufficiency, resent myocardial infarction, cerebrovascular disease, chronic renal failure, or marked bradycardia.
Association with dizziness, somnolence, sedation, and dry mouth.
Should be used with caution with any medications that decrease pulse or blood pressure to avoid the risk of excessive bradycardia and hypotension.
Can prolong QT interval.
Potentiates the depressing effects of benzodiazepines and may potentiate the CNS depressant effects of alcohol, barbiturates and others are dating drugs.
Treatment should be discontinued with gradual dose reduction.